Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multi-Center Randomized Clinical Trial Correlating the Effects of 24 Months of Exemestane or Letrozole on Surrogate Markers of Response With Aromatase Polymorphism

Next Previous
X
Search
Trial Profile

A Multi-Center Randomized Clinical Trial Correlating the Effects of 24 Months of Exemestane or Letrozole on Surrogate Markers of Response With Aromatase Polymorphism

Status: Active, no longer recruiting
Phase of Trial: Phase IV

Latest Information Update: 21 Jul 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Exemestane (Primary) ; Letrozole (Primary)
  • Indications Carcinoma; Early breast cancer
  • Focus Pharmacodynamics; Pharmacogenomic; Therapeutic Use
  • Acronyms ELPh

    • Most Recent Events

    • 07 Jun 2022 Results (n=131) assessing the relationship between use of prescription and over-the-counter (OTC) medications and AI discontinuation in older women, presented at the 58th Annual Meeting of the American Society of Clinical Oncology.
    • 31 May 2020 Results (n=228) identifying, genetic variants that affect steady state letrozole concentrations in patients with breast cancer, presented at the 56th Annual Meeting of the American Society of Clinical Oncology
    • 01 Jul 2017 According to results published in the Breast Cancer Research and Treatment Journal, after 132 patients had been enrolled, an amendment to the protocol allowed patients with self-reported intolerance to the aromatase inhibitor (AI) to which they were originally randomized to crossover to the other study-provided AI.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top